TIME100 Health: Ivan Cheung | TIME
In the pharmaceutical world, where ideas far outnumber marketable products, executives adhere to the motto of “fail often, and fail early,” with the understanding that to do so requires the discipline to know when to cut their losses and say no. But Ivan Cheung followed other advice as CEO of Eisai, Inc. “The opposite is also true,” he says. “You have to have the discipline to say yes when everybody is trying to tell you to say no.”Cheung took a big risk in 2019 when he decided to continue developing lecanemab—which became the second treatment approved to address the root causes of Alzheimer’s disease—when data from aducanumab, which works in a similar way, showed conflicting results and experts questioned the approach. But Cheung’s team showed him promising early results on their drug, an...










